Jochen Salfeld

5.9k citations

29 papers · 4.7k indexed · 3 hit papers · h-index 20

Impact in

Immunology top 1%
- Immune Response and Inflammation
Hepatology top 2%
- Hepatitis C virus research

Papers in

Hepatology 9
- Hepatitis C virus research 9
Rheumatology 6
- Rheumatoid Arthritis Research and Therapies 5
- Systemic Lupus Erythematosus Research 4

Co-authors: Daniel E. Tracey Eric H. Sasso Paul P. Tak Lars Klareskog Heinz Schaller Eberhard Pfaff Winnie W. Wong Wei Fang
Journals: Journal of Virology (3 papers)The EMBO Journal (2 papers)Journal of Hepatology (1 paper)Clinical Pharmacology & Therapeutics (1 paper)Biotechnology Progress (1 paper)
Partner nations: United States Germany Netherlands

In The Last Decade

Jochen Salfeld

28 papers receiving 4.6k citations

Hit Papers

align trajectories log scale

Tumor necrosis factor antagonist mechanisms of action: A comprehensive review 2007 · 1.2k citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2007 Pharmacology & Therapeutics
2004 New England Journal of Medicine
1995 Cell

Peers

Countries citing papers authored by Jochen Salfeld

Since Specialization

Citations

This map shows the geographic impact of Jochen Salfeld's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jochen Salfeld with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jochen Salfeld more than expected).

Fields of papers citing papers by Jochen Salfeld

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jochen Salfeld. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jochen Salfeld. The network helps show where Jochen Salfeld may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Jochen Salfeld, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Jochen Salfeld Line = papers co-authored together Jochen Salfeld links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Anti–Tumor Necrosis Factor With a Glyco-Engineered Fc-Region Has Increased Efficacy in Mice With Colitis Gastroenterology ·Felicia M. Bloemendaal, Alon D. Levin, Manon E. Wildenberg, Pim J. Koelink, Bradford L. McRae, Jochen Salfeld, Prof. V. Vijay Lakshimi, Marijn van der Neut Kolfschoten, Jill Claassens, Remco Visser, Arthur E. H. Bentlage, Geert D’Haens, J. Sjef Verbeek, Gestur Vidarsson, Gijs R. van den Brink	2017	27
2	Fc Receptor-mediated Effector Function Contributes to the Therapeutic Response of Anti-TNF Monoclonal Antibodies in a Mouse Model of Inflammatory Bowel Disease Journal of Crohn s and Colitis ·Bradford L. McRae, Alon D. Levin, Manon E. Wildenberg, Pim J. Koelink, Peter F. Bousquet, Igor Mikaelian, Abou El-Makarim Aboueissa, Shaughn H. Bryant, Geert D’Haens, Rajesh V. Kamath, Jochen Salfeld, Gijs R. van den Brink	2015	26
3	CD11c as a Transcriptional Biomarker to Predict Response to Anti-TNF Monotherapy With Adalimumab in Patients With Rheumatoid Arthritis Clinical Pharmacology & Therapeutics ·Bruno Stuhlmüller, Thomas Häupl, С.В. Клементьев, Andreas Grützkau, RJ Kuban, Neeraj Tandon, J W Voss, Jochen Salfeld, Raimund W. Kinne, Gerd R Burmester	2009	62
4	Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor Clinical Immunology ·Zehra Kaymakcalan, Paul Sakorafas, Sahana Bose, Susanne M. Scesney, ترجمه و تلخیص دکتر ناصر صبحخیز, Swati Narayan, Jochen Salfeld, Eric H. Sasso	2009	248
5	Expression of antibodies using single‐open reading frame vector design and polyprotein processing from mammalian cells Biotechnology Progress ·Yune Z. Kunes, Halil Safak Uygur, Emma Fung, Jochen Salfeld, Rongrong Zhu, Paul Sakorafas, Gerald Carson	2009	8
6	Isotype selection in antibody engineering Nature Biotechnology ·Jochen Salfeld	2007	175
7	The biotechnology era: has the promise been fulfilled? Expert Opinion on Drug Discovery ·Jochen Salfeld	2007	0
8	Tumor necrosis factor antagonist mechanisms of action: A comprehensive review Pharmacology & Therapeutics ·Daniel E. Tracey, Lars Klareskog, Eric H. Sasso, Jochen Salfeld, Paul P. Tak Hit paper breakdown →	2007	1246
9	Use of new biotechnology to design rational drugs against newly defined targets Best Practice & Research Clinical Rheumatology ·Jochen Salfeld	2004	8
10	Anti–Interleukin-12 Antibody for Active Crohn's Disease New England Journal of Medicine ·Peter Mannon, Ivan J. Fuss, Lloyd Mayer, Charles O. Elson, William J. Sandborn, Daniel H. Present, Svetlana Mnaydarova, Nancy Goodman, Catherine Groden, Ronald L. Hornung, Martha Quezado, Markus F. Neurath, Jochen Salfeld, Geertruida M. Veldman, Ullrich Schwertschlag, Warren Strober Hit paper breakdown →	2004	628
11	A SINGLE DOSE PLACEBO CONTROLLED PHASE I STUDY OF THE FULLY HUMAN ANTI-TNF ANTIBODY D2E7 IN PATIENTS WITH RHEUMATOID ARTHRITIS Arthritis & Rheumatism ·Leo van de Putte, Piet L. C. M. van Riel, Alfons A den Broeder, Oliver Sander, Rolf Rau, Christina Binder, Klaus Krüger, M Schattenkirchner, Helmut Fenner, Jochen Salfeld, Jonathan Nicolas, H. Küpper, J. Kempeni	1998	21
12	EFFICACY AND TOLERABILITY OF WEEKLY SUBCUTANEOUS INJECTIONS OF THE FULLY HUMAN ANTI-TNF-ANTIBODY D2E7 IN PATIENTS WITH RHEUMATOID ARTHRITIS-RESULTS OF A PHASE I STUDY Arthritis & Rheumatism ·Jochen Salfeld, Zehra Kaymakcalan, Daniel E. Tracey, Amy E. Roberts, H Choukour	1998	57
13	Mice deficient in IL-1β-converting enzyme are defective in production of mature IL-1β and resistant to endotoxic shock Cell ·Ping Li, Hamish Allen, Subhashis Banerjee, Simon Franklin, M. Wiesenauer B. Ostermayr, HG Sun, J. J. McDowell, Michael Paskind, VICTOR JEMIMA, Jochen Salfeld, E. Gene Towne, Daniel E. Tracey, Scott Wardwell, Wei Fang, Winnie W. Wong, Robert Kamen, Tara Seshadri Hit paper breakdown →	1995	1225
14	Expression and structural and functional properties of human ferritin L-chain from Escherichia coli Biochemistry ·Sonia Levi, Jochen Salfeld, Gultneh Solomon, Anna Cozzi, 文彰谷, Paolo Arosio	1989	113
15	Antigenic determinants and functional domains in core antigen and e antigen from hepatitis B virus Journal of Virology ·Jochen Salfeld, Eberhard Pfaff, M Noah, Heinz Schaller	1989	223
16	Detection of antibodies to proteins encoded by the X-region of hepatitis B virus (HBV) in sera of patients with chronic HBV infection: correlation with other HBV markers. PubMed ·Lorenz Theilmann, Jochen Salfeld, B Kommerell, Eberhard Pfaff	1988	1
17	Pre-S1 proteins in sera of patients positive for HBsAg and antibodies to hepatitis delta virus. PubMed ·Lorenz Theilmann, K. Gmelin, MV Agrez, Jochen Salfeld, B Kommerell, Eberhard Pfaff	1987	1
18	Synthesis of the X-protein of hepatitis B virus in vitro and detection of anti-X antibodies in human sera Virology ·Eberhard Pfaff, Jochen Salfeld, K. Gmelin, Heinz Schaller, Lorenz Theilmann	1987	37
19	Detection of Pre–S1 Proteins in Serum and Liver of Hbsag–Positive Patients: A New Marker for Hepatitis B Virus Infection Hepatology ·Lorenz Theilmann, Mo‐Quen Klinkert, K. Gmelin, Jochen Salfeld, Heinz Schaller, Eberhard Pfaff	1986	51
20	Structure of human ferritin light subunit messenger RNA: comparison with heavy subunit message and functional implications. Proceedings of the National Academy of Sciences ·M. Dörner, Jochen Salfeld, Horst Will, Elizabeth A. Leibold, J. Keith Vass, Hamish N. Munro	1985	43

About Jochen Salfeld

Jochen Salfeld is a scholar working on Hepatology, Rheumatology, Radiology, Nuclear Medicine and Imaging, Epidemiology and Immunology, having authored 29 papers that have together received 4.7k indexed citations. Recurring topics across this work include Hepatitis B Virus Studies (11 papers), Hepatitis C virus research (9 papers), Monoclonal and Polyclonal Antibodies Research (8 papers), Rheumatoid Arthritis Research and Therapies (5 papers), Systemic Lupus Erythematosus Research (4 papers), Viral gastroenteritis research and epidemiology (3 papers), Chronic Lymphocytic Leukemia Research (3 papers) and Immunodeficiency and Autoimmune Disorders (3 papers). The work is most often cited by research in Immunology (1.9k citations), Hepatology (512 citations), Rheumatology (671 citations), Hematology (475 citations) and Epidemiology (1.3k citations). Jochen Salfeld has collaborated with scholars based in United States, Germany and Netherlands. Frequent co-authors include Daniel E. Tracey, Eric H. Sasso, Paul P. Tak, Lars Klareskog, Heinz Schaller, Eberhard Pfaff, Winnie W. Wong, Wei Fang, J. J. McDowell and Tara Seshadri. Their work appears in journals such as Journal of Virology, The EMBO Journal, Journal of Hepatology, Clinical Pharmacology & Therapeutics and Biotechnology Progress.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact